INS and diabetes mellitus: A total 667,567 sensors from 22,006 CGM users were available for analysis, with 13,213 users with T1 diabetes, 5937 users with T2 diabetes treated with basal-bolus insulin/pump, 1281 users with T2 diabetes treated with basal only insulin, and 1575 T2D users not on insulin therapies (Table 1).